Go to navigation Go to content
Toll-Free: (888) 606-5297
Phone: (859) 578-4444
Schachter, Hendy & Johnson, Attorneys At Law

Testosterone Sales Slow in Light of Safety Risks

Sarah N. Emery
Associate Attorney at Schachter Hendy & Johnson PSC
Posted on Nov 07, 2014

Thanks to aggresive direct to consumer advertising asking men who were tired to talk to their doctors about "low T," sales of testosterone drugs totaled $2.2 billion in 2013.

However, the FDA's concerns about the safety of testosterone may be changing this trend. In September 2014, an advisory panel to the FDA voted 20 to 1 to revise the labeling of testosterone drugs to make it clear that the products are intended for serious testosterone deficiencies and not "low T." A majority of the panel also urged the FDA to conduct safety trials in light of multiple studies indicating a risk of heart attack and stroke, in addition to the recently added risks of blood clots in the legs and lungs.

In light of these safety concerns, testosterone is no longer the booming business that it once was. Auxilium Pharmaceuticals, the makers of Testim, cut 190 sales jobs in September due to the plummeting demand for testosterone and then agreed to a $2.6 billion buyout by Endo International. AbbVie reported sales of AndroGel dropped 5% in the first half of 2014 to $472 million, likely meaning that AndroGel will no longer be a blockbuster drug (a drug with sales of more than $1 billion annually).  IMS reports that total sales of testosterone drugs fell 6 percent in the first half of 2014.

If you or a loved one suffered a heart attack, stroke, pulmonary embolism, congestive heart failure or a blood clot as a result of taking a testosterone medication, like AndroGel, please call our experienced testosterone attorneys at (888) 606-5297 for a free consultation about your potential AndroGel lawsuit.

Read More About Testosterone Sales Slow in Light of Safety Risks...

Live Chat